UONDDL
SYRE icon

University of Notre Dame du Lac’s Spyre Therapeutics SYRE Stock Holding History

University of Notre Dame du Lac’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-577,616
Closed -$12.4M – 2
2023
Q4 		$12.4M Buy
+577,616
New +$7.96M 12.73% 2

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

University of Notre Dame du Lac's SYRE Position: Q1 2024 in Review

University of Notre Dame du Lac sold out of Spyre Therapeutics (SYRE) in Q1 2024, closing a stake of 577,616 shares — an estimated $12.4M sold.

University of Notre Dame du Lac first reported a position in SYRE in Q4 2023 and held it in 1 quarter. The position peaked at $12.4M in Q4 2023. 103 funds tracked by Wall St. Rank hold SYRE as of Q1 2024.

  • University of Notre Dame du Lac reported no remaining Spyre Therapeutics position as of Q1 2024 after selling out during the quarter.
  • University of Notre Dame du Lac sold 577,616 Spyre Therapeutics shares in Q1 2024, an estimated $12.4M.
  • University of Notre Dame du Lac first reported a position in Spyre Therapeutics in Q4 2023 and held it in 1 quarter.
  • University of Notre Dame du Lac's Spyre Therapeutics position peaked at $12.4M in Q4 2023.
  • 103 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q1 2024.

Based on University of Notre Dame du Lac's 13F filing for Q1 2024, filed 14 May 2024.